Canada-UK Workshop Participant List

A Canada-UK Workshop: "Beating the Bugs"

Canada House, London, 6-7 February 2008

Canadian participants


Name Affiliation Area of Research
Yossef Av-Gay University of British Columbia
Division of Infectious Diseases
Room 440D HP East
2733 Heather St. Vancouver,
BC V5Z 3J5
604-603-1806
yossi@interchange.ubc.ca
Genetics, TB; Mycobacterium tuberculosis (Mtb); novel methods to identify inhibitors by screening large numbers of compounds to identify those that make Mtb antibiotic sensitive; Protein Kinases as novel drug targets for TB Therapeutics, innate resistance provided by Mycothiol.
Lorne Babiuk University of Alberta
3-7 University Hall
Edmonton, AB T6G 2J9
780-492-5353
lorne.babiuk@ualberta.ca
Vaccines, innate immunity, novel vaccine development, infectious diseases.
Michel G. Bergeron
Université Laval
Centre de recherche en infectiologie du CHUL
2705, boul. Laurier,
Québec City, QC G1V 4G2
418-654-2705
Michel.G.Bergeron@crchul.ulaval.ca
Rapid DNA diagnostic tests for the detection of microbes; Development of compact disc (CD) which can detect nucleic acids (Point-of-care test); Microbicides (Invisible Condom®); Immunotargeting of HIV in lymph mode.
Edith Blondel-Hill British Columbia Children's Hospital
Department of Laboratory Medicine 2G5
4500 Oak Street
Vancouver, BC V6H 3N1
604-875-2345 ext 7649
ebhill@cw.bc.ca
Antimicrobial utilization; guideline and policy development for antibiotic use and prescribing; mechanisms of resistance; susceptibility testing.
Judy Bray CIHR - Institute of Infection
and Immunity (III)
Room 97, 160 Elgin Street
Address Locator: 4809A
Ottawa, ON K1A 0W9
613-954-7223
jbray@cihr-irsc.gc.ca
The CIHR Institute of Infection and Immunity (III) supports research and helps to build research capacity in the areas of infectious disease and the body's immune system. Through the Institute's programs, researchers address a wide range of health concerns related to infection and immunity including disease mechanisms, disease prevention and treatment, and health promotion through public policy.
Lori Burrows Master University
Dept. of Biochemistry
and Biomedical Sciences
4H18 Health Sciences Centre,
1200 Main Street West,
Hamilton, ON L8N 3Z5
905-525-9140 ext. 22029
burrowl@mcmaster.ca
Type IV pili and type II secretion systems in Pseudomonas aeruginosa; the role of peptidoglycan structure in expression of secretion and motility systems; biofilm formation and prevention; and development of novel antimicrobial compounds.
Anthony Clarke
University of Guelph
Science Complex
Guelph, ON N1G 2W1
519-824-4120 ext. 53362
aclarke@uoguelph.ca
Enzymology of peptidoglycan metabolism; mechanism of action of penicillin-binding proteins; pathways for O-acetylation and de-O-acetylation of peptidoglycan; structure-function relationship and mechanism of action of lytic transglycosylases; bacterial resistance to beta lactam antibiotics; broad spectrum beta lactamase inhibitors; interaction of beta lactamases with beta lactam antibiotics and with inhibitors.
Alan Davidson University of Toronto
Department of Biochemistry,
and Dept. of Molecular Genetics
Medical Sciences Building, Room 4285
1 King's College Circle
Medical Sciences Building
Room 5207
Toronto, ON M5S 1A8
416-978-0332
alan.davidson@utoronto.ca
Antibiotic resistance; bacteriophage therapy, specialized phage-tail structures called pyocins that are produced by Pseudomonas bacteria; novel antibacterial therapies for the pathogens Pseudomonas aeruginosa and Staphylococcus aureus.
Julian Davies University of British Columbia (Professor Emeritas)
Department of Microbiology and Immunology Life Sciences Institute
2350 Health Sciences Mall Vancouver, BC V6T 1Z3 604-822-5856
jed@interchange.ubc.ca
Microbial ecology; origins and mechanisms of antibiotic resistance in bacteria; gene capture and horizontal gene transfer; degradation pathways of xenobiotics and lignin-derived products by streptomycetes; non-cultivable bacterial species; genes for antibiotic biosynthetic pathways; isolation of novel secondary metabolites for pharmaceutical application; novel antibiotics; resistance mechanisms; xenobiotic degradation; the biology of antibiotics (discovery, production, function, and resistance); mechanisms of horizontal gene transfer and environmental microbiology
Jonathan Dennis University of Alberta
Department of Biological Sciences
CW 405, Biological Sciences Centre
M 354, Biological Sciences Bldg.
Edmonton, AB T6G 2E9
780-492-2529
jon.dennis@ualberta.ca
Bacteriophages; Burkholderia cepacia complex and their phages; Phage aerosols; Efflux pumps; Antibiotic resistance and solvent tolerance; Mobile genetic elements; Plasmids
Jennifer Gardy
University of British Columbia
CMDR - Room 222A,
2259 Lower Mall, Vancouver,
V6T 1Z4
604-827-4005
jennifer@cmdr.ubc.ca
Pathogenesis of innate immunity; host defence peptides; database creation - key genes, proteins and interactions; systems biology; computational modelling, perturbations of innate immune networks.
Bob Hancock University of British Columbia
Centre for Microbial Diseases
and Immunity Research
Lower Mall Research Station, UBC
Room 232 - 2259 Lower Mall
Vancouver, BC V6T 1Z4
604-822-2682
bob@cmdr.ubc.ca
Gram-negative bacterial surfaces; antibiotic uptake and resistance; host defence (antimicrobial) peptides (a component of the immune system that kills bacteria); genetics/genomics of P. aeruginosa; selective modulation of the innate immune response; novel therapeutics based on the immunomodulatory and antibiotic activities of host defence peptides; regulation of resistance and virulence.
David Heinrichs University of Western Ontario
room 215
Sieben's Centre
London, ON N6A 5C1
519-661-3984
deh@uwo.ca
Novel anti-infective therapeutics that can both treat and prevent S. aureus (particularly MRSA) infections: S. aureus pathogenicity; identification and validation of highly selective targets that are essential in the acquisition of iron, the critical nutrient for S. aureus, from the infected host; development and validation of therapeutic antibodies against these iron acquisition targets that will prevent the pathogen's ability to survive in
the host.
Walid Houry University of Toronto
1 King's College Circle
Medical Sciences Building, Room 5308
Program in Proteomics and Bioinformatics
Department of Biochemistry
Toronto, ON M5S 1A8
416-946-7141
walid.houry@utoronto.ca
Molecular chaperones; proteases;
self-compartmentalizing cylindrical serine protease - ClpP ; activators of cylindrical proteases (ACP) as a novel class of antibiotics.
Allison McGeer
Mount Sinai Hospital, Toronto
Department of Microbiology,
Room 210
600 University Ave,
Toronto, ON M5G 1X5
416-586-3118
amcgeer@mtsinai.on.ca
Prevention of serious bacterial and viral infections in adults; use of surveillance to answer research questions and change practice;. Prevention, diagnosis and treatment of infectious diseases; Clostridium difficile associated diarrhea (CDAD); creation of prediction rules for severe CDAD and also relapsing CDAD; definition of a group of high risk patients; new therapeutic strategies.
Michael Mulvey University of Manitoba, Public Health Agency of Canada
National Microbiology Laboratory
Winnipeg, MB R3E 3R2
204-789-2133
michael_mulvey@phac-aspc.gc.ca
Monitoring the emergence of antimicrobial resistant organisms (AROs) in our hospitals and communities including MRSA, C. difficile, VRE. ESBLs, multidrug resistant (MDR) Acinetobacter, Salmonella and S. pneumoniae, and Neisseria gonorrhoeae; AROs in northern communities including antimicrobial prescribing patterns; molecular epidemiology of AROs; development of an educational programs aimed at both health care providers and individuals in the community in an attempt to reduce the prevalence of AROs; proteomics and genomics studies involving epidemic MRSA, C. difficile, and Salmonella Typhimurium DT104.
Marc Ouellette Université Laval
Centre de recherché en infectiologie
CHUQ-pavillon CHUL
2705 bou. Laurier
Québec City, QC G1V 4G2
418-654-2705
Marc.Ouellette@crchul.ulaval.ca
Antimicrobial resistance; mechanisms of resistance in the parasite, Leishmania and the bacteria Streptococcus pneumoniae; development of new tools to diagnose resistance and novel targets for new drugs; novel pathways; potential therapeutic and diagnostic targets; phage therapy; Whole genome analysis.
Subash Sad National Research Council
- University of Ottawa
Research Officer, Immunomodulation
NRC Institute for Biological Sciences (IBS)
1200 Montreal Road, Bldg. M-54, Room 127
Ottawa, ON K1A 0R6
613-993-6015
subash.sad@nrc-cnrc.gc.ca
Innate immune mechanisms, cytokine biology, immune regulation, immune evasion, control of intracellular pathogens, novel lipid-based alternatives to antibiotics, adaptive immune mechanisms, novel vaccine delivery vehicles, cellular immunology, genomics, lipid chemistry.
Bhagi Singh Scientific Director - CIHR Institute of Infection and Immunity (III)
University of Western Ontario
The Siebens-Drake Research Institute
1400 Western Road, Room #224
London, ON N6G 2V4
519-661-3228
bsingh@uwo.ca
The CIHR Institute of Infection and Immunity (III) supports research and helps to build research capacity in the areas of infectious disease and the body's immune system. Through the Institute's programs, researchers address a wide range of health concerns related to infection and immunity including disease mechanisms, disease prevention and treatment, and health promotion through public policy.
David Speert University of British Columbia
Rm 377 Res Ctr 950 W 28th Av
Vancouver, BC V5Z 4H4
604-875-2438
dspeert@cw.bc.ca
Innate host defenses; microbial determinants of pulmonary pathogenesis; lung infections in patients with cystic fibrosis; Pathogenesis of Pseudomonas aeruginosa; pathogenesis of Burkholderia cepacia complex; innate host defense mechanisms, particularly of the lung; molecular epidemiology of bacterial infection; role of macrophages, polymorphonuclear leukocytes and dendritic cells; the role of specific receptor-ligand interactions; biofilm formation/quorum sensing; molecular epidemiology.
Donald Weaver
Dalhousie University
Departments of Medicine
(Neurology) and Chemistry
Halifax, NS B3H 4J3
902-494-7183
donald.weaver@dal.ca
Drugs which can be prescribed in combination with antibiotics to better fight infections; gram-negative bacteria, compounds that interfere with the upkeep of the outer membrane; overcoming resistance.
Gillian Wu York University
Lumbers Building
4700 Keele St.
Toronto, ON M3J 1P3
1-416-7362100 (23070)
gillwu@yorku.ca
UK Contact:
Visiting Fellow,
Clare Hall, University of Cambridge
Herschel Road, Cambridge
CB3 9Al, UK
Ph (from North America) 011 44 1223 332374
Generation of lymphoid diversity; Polymporphisms in the Immune System, especially in Autoimmune Diseases such as Arthritis; determination of variations in responses to antigens including microbial and self antigens

UK participants


Name Affiliation Area of Research
Mike Barer University of Leicester ebhill@cw.bc.ca Clinical Microbiology; Tuberculosis; Chemotherapy of stressed and non--replicating bacteria; Mycobacterial lipid metabolism.
Weng Chan University of Nottingham
Quorum sensing modulators; virulence modulators; anti-infective agents; Gram-positive pathogens; Staphylococcus aureus; peptidomimetics; peptide chemical biology.
Derrick Crook University of Oxford
Adult infectious diseases and clinical microbiology and specialist training; bacterial infections caused by Streptococcus pneumoniae, Streptococcus agalactiae, Haemophilus influenzae and Staphylococcal species; epidemiology; population biology; antibiotic resistance elements; host genetic susceptibility.
Chris Dowson University of Warwick Antibiotic resistance; bacterial pathogenicity; population genetics; molecular basis for the evolution of antibiotic resistance; chemotherapeutic agents or vaccination; regulation of the resistant phenotype, due to the acquisition of resistance determinants or cell physiology
Mark Enright Imperial College London
Epidemiology of infections caused by bacteria; development of genetic tools to track 'superbugs' MRSA as they spread
in human populations; evolution of antibiotic resistance
Gadi Frankel Imperial College London
Host pathogen interaction and transmission, focusing on E. coli O157 and enteropathogenic E. coli (EPEC). Combining novel infection models and imagining methods to study type III secretion system (apparatus and effectors) and infection dynamics, mechanisms of bacterial attachment, colonisation and subversion of cell signalling.
Stephen Gillespie University College London Tuberculosis, drug development, clinical trials, mathematical modelling of treatment effects, diagnostics for
clinical trials.
Peter Hawkey Heart of England NHS Foundation
Molecular evolution of ?-lactamases, aminoglycoside inactivating enzymes and the TET(M) family of transposons; molecular typing methods and the molecular epidemiology of nosocomial bacteria.
Andrew Hayward University College London
Antimicrobial prescribing; antimicrobial resistance; primary care; acute respiratory infection.
Ian Henderson University of Birmingham
Bacterial pathogens; class of virulence determinants; secreted virulence proteins; type V secretion.
Doug Lowrie NIMR The location and form of persister TB bacteria in murine models; the capacity of the bacteria that cause tuberculosis to persist in tissues; sensitive molecular probe technologies and mouse models of persistent infection.
Dietrich Mach University of Swansea
Staphylococcus epidermidis; medical biofilm disease ; intravascular catheters or joint prostheses; S. epidermidis in surface adherent biofilms; polysaccharide intercellular adhesin (PIA); homoglycan of b -1,6 -linked N- acetylglucosamine residues; isogenic biofilm-negative icaA-insertion mutants expression of PIA and biofilm formation; essential virulence factors of S. epidermidis in foreign body infection models; isogenic biofilm -negative mutants with regulatory defects in transcription of icaADBC; allelic gene replacement analysis of regulatory gene loci.
Laura Piddock University of Birmingham
Antibiotic resistance in enteric bacteria (Salmonella, Campylobacter, Escherichia coli); efflux pumps in both antibiotic resistance and pathogenicity.
David Roper University of Warwick
Structural and molecular enzymology of antibiotic resistance mechanisms particularly in respect of Vancomycin and beta-lactam resistance. Biosynthesis of peptidoglycan in Gram positive and negative pathogens.
Peter Taylor London School of Pharmacy
Novel Antibacterial Therapies; Natural Products with Antibacterial Activity; Overcoming Resistance to Antibiotics; MRSA; Complement; Bacterial Neonatal Meningitis; Bacteriophage Enzymes as Therapeutics; Escherichia coli.
Liz Wellington University of Warwick
Characterisation of bacterial and fungal microorganisms in soil; analysis of bacterial gene expression; detection, quantification and activity of specific bacterial and fungal communities; pathogen survival in soi; analysis of soil microbial communities.
Paul Williams University of Nottingham Bacterial cell-to-cell communication (quorum sensing), gene regulatory networks and the control of virulence and biofilm gene expression; post-transcriptional gene regulation; quorum sensing systems as antibacterial targets; discovery and development of novel antibacterial agents.
Neil Woodford Health Protection Agency
Reference bacteriology; resistance mechanisms; molecular epidemiology; susceptibility testing; antisense antibacterials
Brendan Wren London School of Hygiene and
Tropical Medicine
Evolution of bacterial virulence; development of novel conjugate vaccines using protein glycan coupling technology; application of systems biology to understand host pathogen interactions.
Wilma Ziebuhr Queen's University Belfast Epidemiology of heathcare-associated biofilm-forming, multiresistant Staphylococci; mechanisms of genome flexibility and horizontal gene transfer; effect of subinhibitory antibiotic concentrations on gene expression and metabolism; novel antimicrobial compounds.
Brian Duerden Department of Health
Inspector of Microbiology and Infection Control at the Department of Health. Responsible for ensuring the quality and consistency of clinical and public health microbiology services.
Bill Maton-Howarth Department of Health
Chief Research Officer for Public Health.
Jo Dekkers Medical Research Council
Programme Manager for Infections and Immunity Board.
Peter Dukes Medical Research Council
Board Programme Manager for Infections and Immunity Board.
Claire Kidgell Wellcome Trust
Science Programme Officer, Immunology and Infectious Disease.

Other participants

Shiva Amiri, Science & Innovation Officer, British Consulate General, Toronto
Leszek Borysiewicz, Chief Executive, Medical Research Council, UK
Richard Davis, Wellcome Trust
Mike Jeapes, Medical Research Council, UK
Graham Baker, Technology Development Officer, High Commission of Canada
Catherine Dickson, Counsellor (Trade, Investment, S&T), High Commission of Canada
Tina Hodges, Science & Technology Assistant, High Commission of Canada
Caroline Martin, Manager, Science & Technology Programme, High Commission of Canada
Guy Sainte-Jacques, Deputy High Commissioner for Canada

Date modified: